Building on this, we optimized the electroporation conditions and employed a circRNA-electroporation strategy to engineer CAR-T cells targeting Delta-like ligand 3 (DLL3), a prominent target in small cell lung cancer (SCLC). This evidence concerns the gene DLL3 and small cell lung carcinoma.